Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment

被引：0
|
作者：
Martorell, C. [3 ]
Ward, D. [2 ]
Short, W. S. [4 ]
Ramgopal, M. [5 ]
Das, M. [1 ]
Nguyen-Cleary, T. [1 ]
Shave, A. [1 ]
McCallister, S. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] DuPont Circle Phys, Washington, DC USA
[3] Res Inst, Springfield, MA USA
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Midway Immunol & Res Ctr, Ft Pierce, FL USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2017年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
C86
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected adults on chronic haemodialysis
    Eron, J.
    Kalayjian, R.
    Wurapa, A.
    Stephens, J.
    McDonald, C.
    Wilkin, A.
    McKellar, M.
    Custodio, J.
    Jiang, S.
    SenGupta, D.
    Castles, R.
    Das, M.
    [J]. HIV MEDICINE, 2018, 19 : S16 - S16
  • [2] Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women Text
    Hodder, Sally
    Squires, Kathleen
    Kityo, Cissy
    Hagins, Debbie
    Avihingsanon, Anchalee
    Kido, Anna
    Jiang, Shuping
    Kulkarni, Rima
    Cheng, Andrew
    Cao, Huyen
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) : 209 - 213
  • [3] Common adverse drug reactions of elvitegravir, cobicistat, and emtricitabine co-formulated with tenofovir alafenamide or tenofovir disoproxil fumarate
    Segal-Maurer, S.
    Henry, K.
    Benson, P.
    Brinson, C.
    Crofoot, G.
    Guo, S.
    Esser, P.
    Nguyen-Cleary, T.
    Das, M.
    McCallister, S.
    [J]. ANTIVIRAL THERAPY, 2016, 21 : A51 - A51
  • [4] Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data
    Tabak, Fehmi
    Zerdali, Esra
    Altuntas, Ozlem
    Gunduz, Alper
    Bolukcu, Sibel
    Mete, Bilgul
    Nakir, Inci Y.
    Kumbasar Karaosmanoglu, Hayat
    Yildiz, Dilek S.
    Meric Koc, Meliha
    Dokmetas, Ilyas
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (06) : 562 - 569
  • [5] Safety and Tolerability of Co-formulated Tenofovir/Emtricitabine/Elvitegravir/Cobicistat ("Quad") for Non-occupational Post-exposure Prophylaxis
    Mayer, Kenneth H.
    Gregor, Charles
    Gelman, Marcy
    Grasso, Chris
    Melbourne, Kathy
    Mimiaga, Matthew J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A155 - A155
  • [6] Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
    Kuo, Po-Hsien
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Wu, Pei-Ying
    Liu, Wen-Chun
    Hung, Chien-Ching
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 : 71 - 77
  • [7] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
  • [8] Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients
    Huang, Yu-Shan
    Cheng, Chien-Yu
    Liou, Bo-Huang
    Lu, Po-Liang
    Cheng, Shu-Hsing
    Lee, Yuan-Ti
    Liu, Chun-Eng
    Sun, Hsin-Yun
    Yang, Chia-Jui
    Tang, Hung-Jen
    Lin, Shih-Ping
    Ho, Mao-Wang
    Huang, Sung-Hsi
    Tsai, Hung-Chin
    Lee, Chen-Hsiang
    Hung, Chien-Ching
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 473 - 481
  • [9] Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort
    Korten, V.
    Inan, A.
    Akalin, H.
    Gokengin, D.
    Kaya, B.
    Inan, D.
    Ozdemir, H. Ozkan
    Azak, E.
    Dogru, A.
    Dokuzoguz, B.
    Yildirmak, T.
    Kose, S.
    Karaoglan, I.
    [J]. HIV MEDICINE, 2019, 20 : 58 - 58
  • [10] A Review of the Efficacy and Safety of Genvoya (R) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection
    Angione, Sara A.
    Cherian, Sibyl M.
    Ozdener, Ayse Elif
    [J]. JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 216 - 221
12345